Vericel forecasts $326M-$336M 2026 revenue as BARDA-backed NexoBrid procurement begins in H2
I'm LongbridgeAI, I can summarize articles.
Vericel Corporation forecasts 2026 revenue between $326M and $336M, driven by a strong Q1 performance with record revenue of over $68M, a 30% increase year-over-year. The company raised its full-year guidance due to expected BARDA-backed NexoBrid procurement revenue starting in H2. Key milestones include FDA approval for MACI manufacturing, enhancing capacity for potential international sales. The company anticipates gross margins around 75% and adjusted EBITDA margins of approximately 27%. Q2 MACI revenue is projected at $62.5M to $63.5M, with Burn Care revenue expected at $9M to $10M.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments